We treated the TAC mice with LY294002 (a PI3K inhibitor that prevents PI3K phosphorylation) or Venetoclax (a selective Bcl-2 inhibitor) as described in Methods and Materials. Here, BCL2 is linked to persistent truncus arteriosus.